Applied Filters
Amarin vows to challenge Vascepa patent ruling
Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.
Gilead signs deal to license new cancer treatment
Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells.
Teva charged in DoJ antitrust probe into generic drug price-fixing
Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.
Intercept sues Apotex over Ocaliva generic
Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
Mylan launches Tecfidera generic amid Biogen battle
Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.
FDA approves Dr Reddy’s Vascepa generic
Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
Teva sues Cipla over generic asthma inhalers
Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.
BMS, Pfizer secure victory over generic makers
In a victory for Bristol-Myers Squibb and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis.
